Role of sialic acid and alkaline DNase in breast cancer

Serum levels of sialic acid and alkaline DNase (ADA) were analysed in 495 blood samples collected from 170 breast cancer patients before and during/after anticancer treatment. Fifty-six healthy females were included in the study to define the cutoff values. The markers were analysed by highly sensit...

Full description

Saved in:
Bibliographic Details
Published inThe International journal of biological markers Vol. 12; no. 2; p. 61
Main Authors Raval, G N, Parekh, L J, Patel, M M, Patel, P S, Rawal, R M, Balar, D B, Patel, D D
Format Journal Article
LanguageEnglish
Published United States 01.04.1997
Subjects
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Breast Neoplasms - blood
Breast Neoplasms - diagnosis
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Colorimetry - methods
Deoxyribonucleases - blood
Female
Follow-Up Studies
Humans
Lipids - blood
Middle Aged
N-Acetylneuraminic Acid - blood
Neoplasm Staging
Reproducibility of Results
Sensitivity and Specificity
Sialic Acids - blood
Spectrophotometry, Ultraviolet - methods
Online AccessGet more information

Cover

More Information
Summary:Serum levels of sialic acid and alkaline DNase (ADA) were analysed in 495 blood samples collected from 170 breast cancer patients before and during/after anticancer treatment. Fifty-six healthy females were included in the study to define the cutoff values. The markers were analysed by highly sensitive spectrophotometric methods. Statistical evaluation of the data was done using Student's 't' test, paired 't' test and ROC curve analysis. The total sialic acid (TSA), lipid bound sialic acid (LSA) and ADA in sera of untreated breast cancer patients were significantly higher than in controls. ROC curve analysis revealed TSA and LSA to be useful markers for diagnosis of breast cancer. Serum levels of TSA and LSA were significantly decreased in complete responders as compared to their pretreatment values. The pretreatment ADA values showed much individual variation. However, responders showed higher levels of ADA than untreated patients. In nonresponders the values of the biomarkers were comparable with pretreatment levels. The study suggested that TSA and LSA can be helpful in the diagnosis of breast cancer. All three markers can be used for assessment of response to anticancer treatment in breast cancer patients.
ISSN:0393-6155
DOI:10.1177/172460089701200204